Welcome PDCI New Hires!

Recognizing the increasing demand for PDCI expertise and the growing needs of our clients, we are proud to announce the addition of new staff in our Health Technology Assessment (HTA) and Reimbursement Strategy Teams. Background Our vision at PDCI is to be the most trusted and valued pricing and reimbursement strategic partner. ... Read More


PDCI Market Access is delighted to participate in the 4th Annual Canadian Institute’s Pharma Symposium. The Pharma Symposium brings together leading stakeholders from pharmaceutical manufacturers, public/private payers, agencies, regulatory bodies and patient groups to analyze the key issues facing the industry in today’s complex environment. Participants will gain insights as ... Read More


On January 29, 2018, PDCI released a report critically evaluating Health Canada’s plan to change how patented medicine prices are regulated in Canada. PDCI’s report - entitled Proposed Amendments to the Patented Medicines Regulations: A Critical Appraisal of the Cost-Benefit Analysis – includes perspectives on the Regulatory Impact Assessment Statement ... Read More




The mandatory public consultation process must be a tiresome inconvenience for Health Canada policy makers.  At least that’s the perception from the release of its proposed amendments to the Patented Medicines Regulations (Regulations) and the accompanying Regulatory Impact Assessment Statement (RIAS) published in Canada Gazette Part I last week.  Why ... Read More


Join us for a webinar on Dec 06, 2017 at 2:00 PM EST. Register now! Join PDCI’s Founder and Principal Consultant, Neil Palmer on this industry only webinar as he discusses the proposed amendments to the Patented Medicines Regulations as published in Canada Gazette Part 1 on December 2, 2017. What ... Read More


Proposed regulatory text of amendments to the Patented Medicines Regulations is published by the Governor-in-Council in Canada Gazette Part I (CG1) on December 2, 2017.  Interested persons may submit comments on the proposed regulations within 75 days of publication in CG1 (by ... Read More


It is with great pleasure to announce after several months of a successful strategic partnership with Roubaix Strategies Inc. (RSI), John-Paul Dowson is formally joining the PDCI team as our new Director of Reimbursement Strategy. John-Paul brings more than 20 years of senior experience working in the health and pharmaceutical sectors. ... Read More


We are pleased to announce that effective October 30, 2017 Jennifer Haig has joined PDCI Market Access Inc. as Manager, HTA and Health Economics. Jen joins our growing HTA team and brings extensive experience with Pharmacoeconomic and Budget Impact modelling. Prior to joining PDCI, Jen was a market access and health ... Read More